PMID- 23845326
OWN - NLM
STAT- MEDLINE
DCOM- 20140319
LR  - 20201209
IS  - 1873-2763 (Electronic)
IS  - 1873-2763 (Linking)
VI  - 56
IP  - 2
DP  - 2013 Oct
TI  - Increased serum sclerostin and decreased serum IGF-1 are associated with 
      vertebral fractures among postmenopausal women with type-2 diabetes.
PG  - 355-62
LID - S8756-3282(13)00247-0 [pii]
LID - 10.1016/j.bone.2013.06.029 [doi]
AB  - Insulin-like growth factor 1 (IGF-1) is a determinant of bone mass and is 
      inversely associated with vertebral fractures (VFs). Sclerostin regulates bone 
      formation by inhibiting Wnt/beta-catenin signaling. Currently, there is little 
      information on circulating sclerostin levels among postmenopausal women with 
      type-2 diabetes mellitus (T2DM) with VFs in relation to serum IGF-1 (s-IGF-1). We 
      investigated the relationships between serum sclerostin, s-IGF-1, and VFs in 
      postmenopausal women with T2DM. We assessed cross-sectionally 482 postmenopausal 
      women with T2DM and 482 age-matched postmenopausal women without T2DM who were 
      recruited at diabetic clinics and primary health care centers for inclusion in a 
      bone health survey. The main outcome measures were serum sclerostin, s-IGF-1, 
      bone mineral density (BMD), and bone turnover markers. Lateral X-rays of the 
      thoracic and lumbar spine were taken to diagnose VFs. Serum sclerostin levels 
      were increased, whereas s-IGF-1 levels were decreased when T2DM women were 
      stratified by the number of VFs (P<0.0001). Multiple logistic regression analysis 
      showed that serum sclerostin levels were positively associated with 1 VF (odds 
      ratio [OR]=1.27, (95% CI:1.01-2.03), P=0.016), 2 VFs (OR=1.41, (95% 
      CI:1.03-2.36), P=0.006), and >/=3 VFs (OR=1.54, (95% CI:1.12-2.44) P=0.005). 
      s-IGF-1 levels were inversely associated with 1 VF (OR=0.58, (95% CI:0.39-0.88), 
      P=0.041), 2 VFs (OR=0.42, (95% CI:0.21-0.90), P=0.012), and >/=3 VFs (OR=0.19, (95% 
      CI: 0.14-0.27), P<0.001). Increased serum sclerostin and decreased s-IGF-1 were 
      associated with VFs among postmenopausal women with T2DM, suggesting that 
      sclerostin and/or IGF-1 may be involved in increased bone fragility in T2DM and 
      could be potential markers of VF severity.
CI  - (c) 2013 Elsevier Inc. All rights reserved.
FAU - Ardawi, Mohammed-Salleh M
AU  - Ardawi MS
AD  - Center of Excellence for Osteoporosis Research, Faculty of Medicine and King 
      Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia. 
      msmardawi@yahoo.com
FAU - Akhbar, Daad H
AU  - Akhbar DH
FAU - Alshaikh, Abdulrahman
AU  - Alshaikh A
FAU - Ahmed, Maimoona M
AU  - Ahmed MM
FAU - Qari, Mohammed H
AU  - Qari MH
FAU - Rouzi, Abdulrahim A
AU  - Rouzi AA
FAU - Ali, Ahmed Y
AU  - Ali AY
FAU - Abdulrafee, Adel A
AU  - Abdulrafee AA
FAU - Saeda, Mamdouh Y
AU  - Saeda MY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130709
PL  - United States
TA  - Bone
JT  - Bone
JID - 8504048
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Bone Morphogenetic Proteins)
RN  - 0 (Genetic Markers)
RN  - 0 (SOST protein, human)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing
MH  - Aged
MH  - Bone Density/physiology
MH  - Bone Morphogenetic Proteins/*blood
MH  - Diabetes Mellitus, Type 2/*blood/*physiopathology
MH  - Female
MH  - Genetic Markers
MH  - Humans
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Middle Aged
MH  - Postmenopause
MH  - Spinal Fractures/*blood
OTO - NOTNLM
OT  - Bone turnover markers
OT  - Diabetes
OT  - IGF-1
OT  - Postmenopausal women
OT  - Sclerostin
EDAT- 2013/07/13 06:00
MHDA- 2014/03/22 06:00
CRDT- 2013/07/13 06:00
PHST- 2013/05/26 00:00 [received]
PHST- 2013/06/26 00:00 [revised]
PHST- 2013/06/29 00:00 [accepted]
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/13 06:00 [pubmed]
PHST- 2014/03/22 06:00 [medline]
AID - S8756-3282(13)00247-0 [pii]
AID - 10.1016/j.bone.2013.06.029 [doi]
PST - ppublish
SO  - Bone. 2013 Oct;56(2):355-62. doi: 10.1016/j.bone.2013.06.029. Epub 2013 Jul 9.